
    
      The trial consists of two parts; a dose escalation part (phase I, first in- human (FIH)) and
      an expansion part (phase IIa).

      The dose escalation part has two dose escalation arms: the first arm investigates a once
      every 3 weeks (1Q3W) dosing schedule and the second arm investigates a three administrations
      over 4 weeks (3Q4W) dosing schedule.

      The Expansion part of the trial will further explore the recommended phase 2 dose and dosing
      regimens of HuMax-AXL-ADC as determined in Part 1
    
  